It has been an incredible year for shareholders of Medical Developments International Ltd (ASX: MVP). Year-to-date the fast-growing healthcare company’s share price has risen a whopping 40%.

Much of this gain can be attributed to the launch of its Penthrox non-opioid pain relief product in a number of markets across the world. Penthrox is the green whistle device that has been used for decades by ambulance officers and surf lifesavers for pain relief here in Australia.

In the last few months alone the company has announced licensing deals in Korea and Canada, as well as regulatory approval in France and the UAE.

The company is working hard behind the scenes and I don’t believe it will be long until we see Penthrox on sale throughout Europe, the United Kingdom, and the United States.

The good news doesn’t stop there though. This morning the company announced a major new deal with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to conduct a research and development program into new manufacturing technologies for pharmaceutical products.

The partnership with CSIRO aims to manufacture existing pharmaceutical products for a fraction of the price. According to CEO John Sharman if the partnership is successful the suite of manufacturing technologies created is expected to be extremely valuable.

Mr Sharman went onto say:

“We will use the knowledge gained from the development of our new Penthrox manufacturing technology to create patentable intellectual property which will be owned by MVP. Our R&D program is very focused and structured and we expect it to show results within two years.”

CSIRO will also benefit from the deal through significant royalty revenues should the partnership be a success.

I’m not at all surprised to see Medical Developments International’s share price jump 5% to $5.10 on the news. In my opinion this is a company with huge potential and an excellent management team.

It is of course early days and the company will have to grow into its lofty valuation in time. For this reason I would suggest investors limit an investment to just a small part of their portfolio. If it is too high risk for you then industry peers CSL Limited (ASX: CSL) and Mayne Pharma Group Ltd (ASX: MYX) might be better options.

If you need to make space in your portfolio for MVP, I would suggest you take a look to see if you own these wealth destroying shares. 

3 Rotten Shares to Sell, and 1 to Buy Today

After a double-digit rally for the ASX since 2016 lows, investors should be on high alert. You'll find a full rundown below of 3 shares we think you should avoid today plus one top pick worth buying, even if the market turns south and the RBA keeps rates at an "emergency low." Simply click here to uncover these stocks.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.